Hyun Bae
Vermögen: 15 256 $ am 31.07.2026
Vermögen: 15 256 $ am 31.07.2026
Dr. Hyun W.
Bae, MD, is an Independent Director at Kairos Pharma Ltd. and a Professor-Orthopaedic Surgery at Cedars-Sinai Medical Center.
He is on the Board of Directors at Kairos Pharma Ltd. Dr. Bae was previously employed as a Chief Medical Officer & Director by Prosidyan, Inc. He received his undergraduate degree from The Trustees of Columbia University in The City of New York and a doctorate degree from Yale University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
KAIROS PHARMA, LTD. 0,23 % | 31.03.2026 | 49 855 ( 0,23 % ) | 15 256 $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| KAIS PHARPAR | Direktor/Vorstandsmitglied | 09.09.2020 |
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center Hospital/Nursing ManagementHealth Services Operates as a hospital | Corporate Officer/Principal | - |
| Unternehmen | Position | Ende |
|---|---|---|
Prosidyan, Inc.
Prosidyan, Inc. Industrial SpecialtiesProcess Industries Develops fiber-based bioactive glass products | Technik-/Wissenschafts-/F&E-Leiter | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
The Trustees of Columbia University in The City of New York
The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center Hospital/Nursing ManagementHealth Services Operates as a hospital | Health Services |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prosidyan, Inc.
Prosidyan, Inc. Industrial SpecialtiesProcess Industries Develops fiber-based bioactive glass products | Process Industries |
Kairos Pharma Ltd.
Kairos Pharma Ltd. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen